Amphotericin B-gum arabic conjugates: Synthesis, toxicity, bioavailability, and activities against Leishmania and fungi

Pharmaceutical Research

Volumn 24, Issue 5, 2007, Pages 971-980

  Nishi, K K ^a   Antony, M ^a   Mohanan, P V ^a   Anilkumar, T V ^a   Loiseau, P M ^b   Jayakrishnan, A ^a  

^a SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

^b UNIVERSITÉ PARIS SUD   (France)

Author keywords

Amphotericin B; Antifungal; Antileishmanial; Bioavailability; Gum arabic; Hemolysis; Polymer drug conjugate; Toxicity

Indexed keywords

AMINE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B GUM ARABIC CONJUGATE; AMPHOTERICIN B LIPID COMPLEX; GUM ARABIC; IMINE; POLYSACCHARIDE; SCHIFF BASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; BRAIN; CANDIDA ALBICANS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TISSUE LEVEL; EXPERIMENTAL RABBIT; FUNGUS CULTURE; HEART; HEMOLYSIS; HISTOLOGY; IC 50; KIDNEY; LEISHMANIA DONOVANI; LIVER; MALE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; TOXICITY TESTING;

EID: 34247580916     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9222-z     Document Type: Article

References (30)

1. A. H. Groll and T. J. Walsh. Uncommon opportunistic fungi: new nosocomial threats. Clin. Microbiol. Infect.7 (Suppl 2):8-24 (2001).
2. T. J. Walsh, J. Hiemenz, and E. Anaissie. Recent progress and current problems in treatment of invasive fungal infections in neuropenic patients. Infect. Dis. Clin. North Am. 10:365-400 (1996).
3. H. A. Gallis, R. H. Drew, and W. W. Pickard. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329 (1990).
4. J. D. Berman. Human leishmaniasis: clinical, diagnostic and chemotherapeutic developments in past 10 years. Clin. Infect. Dis. 24:684-703 (1997).
5. J. Brajtburg, W. G. Powderly, G. S. Kobayashi, and G. Medoff. Mini review. Amphotericin B: current understanding of mechanism of action. Antimicrob. Agent Chemother. 34:183-188 (1990).
6. G. Deray. Amphotericin B nephrotoxicity. J. Antimicrob. Chemother. 49:37-41 (2002).
7. J. Brajtburg and J. Bolard. Carrier effects on biological activities of Amphotericin B. Clin. Microbiol. Rev. 9:512-531 (1996).
8. B. Dupont. Overview of the lipid formulations f amphotericin B. J. Antimicrob. Chemother. 49 (suppl S1):31-36 (2002).
9. V. Yardley and S. L. Croft. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob. Agents Chemother 41:752-756 (1997).
10. S. L. Croft and V. Yardley. Chemotherapy of Leishmaniasis. Curr. Pharm. Des. 8:319-342 (2002).
11. M. Larabi, V. Yardley, P. M. Loiseau, M. Appel, P. Legrand, A. Gulik, C. Bories, S. L. Croft, and G. Barrat. Toxicity and Antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob. Agents Chemother. 47:3774-3779 (2003).
12. R. Falk, A. J. Domb, and I. Polacheck. A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrob. Agents Chemother. 43:1975-1981 (1999).
13. E. Kleinman, T. Azzam, R. Falk, I. Polacheck, J. Golenser, and A. J. Domb. Synthesis and characterization of novel water soluble amphotericin B-arabinogalactan conjugate. Biomaterials 23:1327-1335 (2002).
14. J. Golenser, S. Frankenburg, T. Ehrenfreund, and A. J. Domb. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives. Antimicrob. Agents Chemother. 43:2209-2214 (1999).
15. R. Falk, J. Grunwald, A. Hoffman, A. J. Domb, and I. Polacheck. Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis. Antimicrob. Agents Chemother.48:3606-3609 (2004).
16. N. Matsumori, N. Eiraku, S. Matsuoka, T. Oishi, M. Murata, T. Aoki, and T. Ide. An amphotericin B-ergosterol covalent conjugate with powerful membrane permeabilizing activity. Chem. Biol. 11:673-679 (2004).
17. E. Charvalos, M. N. Tzatzarakis, F. V. Bambeke, P. M. Tulkens, A. M. Tsatsakis, G. N. Tzanakakis, and M.-P. Mingeot-Leclercq. Water-soluble amphotericin-B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp and Aspergillus spp and reduced haemolytic and cytotoxic effects. J. Antimicrob. Chemother. 57:236-244 (2006).
18. D. Verbeken, S. Dierckx, and K. Dewettinck. Mini-review: exudate gums: occurance, production, and applications. Appl. Microbiol. Biotechnol. 63:10-21 (2003).
19. K. K. Nishi and A. Jayakrishnan. Preparation and in vitro evaluation of primaquine-conjugated gum arabic microspheres. Biomacromolecules 5:1489-1495 (2004).
20. S. Raynaud-Le Grandic, C. Fourneau, A. Laurens, C. Bories, R. Hocquemiller, and P. M. Loiseau. In vitro antileishmanial activity of acetogenins from annonaceae. Biomed. Pharmacother. 58:388-392 (2004).
21. National Committee for Clinical Laboratory StandardsReference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M-27A, National Committee for Clinical Laboratory Standards, Wayne, PA, 1997.
22. T. J. Walsh, A. J. Jackson, J. W. Lee, M. Amantea, T. Sein, J. Bacher, and L. Zech. Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits. Antimicrob. Agents Chemother. 44:2068-2076 (2000).
23. J. Barwicz, S. Christian, and I. Gruda. Effects of aggregation of amphotericin B on its toxicity to mice. Antimicrob. Agents Chemother. 36:2310-2315 (1992).
24. M. Larabi, A. Gulik, J. P. Dedieu, P. Legrand, G. Barrat, and M. Cheron. New lipid formulations of Amphotericin B: spectral and microscopic analysis. Biochem. Biophys. Acta.1664:172-181 (2004).
25. P. Legrand, E. A. Romero, B. E. Cohen, and J. Bolard. Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrob. Agents Chemother. 36:2518-2522 (1992).
26. A. B. Mullen, K. C. Carter, and A. J. Baillie. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob. Agents Chemother.41:2089-2092 (1997).
27. M. S. Maddux and A. L. Barriere. A review of complications of amphotericin B therapy: Recommendations for prevention and management. Drug. Intel. Clin. Pharm. 14:177-181 (1980).
28. P. J. Danaher, M. K. Cao, G. M. Anstead, M. J. Dolan, and C. C. DeWitt. Reversible dilated cardiomyopathy related to amphotericin B therapy. J. Antimicrob. Chemother. 53:115-117 (2004).
29. K. Y. Lee, K. H. Bouhadir, and D. J. Mooney. Degradation behaviour of covalently cross-linked poly(aldehyde guluronate) hydrogels. Macromolecules 33:97-101 (2000).
30. T. Boontheekul, H.-J. Kong, and D. J. Mooney. Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. Biomaterials 26:2455-2465 (2005).